Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Urologia ; 89(4): 629-635, 2022 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-34617487

RESUMEN

BACKGROUND: Studies demonstrate that getting antioxidants in the course of treatment has a positive impact beneficial effect on fertility, especially on the quality of sperm. Because of that reason antioxidants are recommended as a potentially influential treatment for infertility in men. However, it is argued that this treatment is not based on sufficient evidence and has no effect on the rate of healthy pregnancy. OBJECTIVE: In this study, two different antioxidant combinations with different doses and contents were evaluated in terms of their effect on sperm parameters. MATERIALS/METHODS: A total of 122 patients diagnosed with idiopathic infertility were enrolled in our multicenter study. The patients were divided into two different groups: The first group used a combination 2 × 1 sachet form (l-carnitine 1 g, acetyl-l-carnitine 0.5 g, fructose 1 g, citric acid 0.50 mg, selenium 50 µg, coenzyme Q10 20 mg, vitamin C 90 mg, zinc 10 mg, folic acid 200 µg, and vitamin B12 1.5 µg) and the second group used a combination tablets form 2 × 1 (l-carnitine 500 mg, selenium 50 µg, coenzyme Q10 20 mg, vitamin C 60 mg, zinc 15 mg, folic acid 400 µg, vitamin E, and ginseng 15 µg) for 6 months. The total semen volume, the total sperm number, sperm concentration, sperm motility, and lastly morphological findings of the patients were compared at the end of 6 months. RESULTS: The mean age of the patients participating in the study was 30.8 ± 6.05 years. No significant difference was found between the two groups in terms of baseline sperm count. There was a significant difference between the baseline and sixth-month values of the patients using both combinations. However, no significant statistical difference was found between the groups according to the sixth-month data. The combinations of both antioxidants had a positive effect on sperm parameters, and the use of different doses and contents had a similar effect. CONCLUSION: Both antioxidants respectively had a positive effect on sperm parameters and also the use of different doses and contents had a similar effect.


Asunto(s)
Infertilidad Masculina , Selenio , Acetilcarnitina/farmacología , Acetilcarnitina/uso terapéutico , Adulto , Antioxidantes/farmacología , Antioxidantes/uso terapéutico , Ácido Ascórbico/farmacología , Ácido Ascórbico/uso terapéutico , Carnitina/farmacología , Carnitina/uso terapéutico , Ácido Cítrico/farmacología , Ácido Cítrico/uso terapéutico , Femenino , Ácido Fólico/farmacología , Ácido Fólico/uso terapéutico , Fructosa/farmacología , Fructosa/uso terapéutico , Humanos , Infertilidad Masculina/tratamiento farmacológico , Masculino , Embarazo , Selenio/farmacología , Selenio/uso terapéutico , Semen , Motilidad Espermática , Espermatozoides , Vitamina B 12/farmacología , Vitamina B 12/uso terapéutico , Vitamina E/uso terapéutico , Adulto Joven , Zinc/farmacología , Zinc/uso terapéutico
2.
Urol J ; 12(6): 2452-6, 2015 Dec 23.
Artículo en Inglés | MEDLINE | ID: mdl-26706745

RESUMEN

PURPOSE: Transurethral resection of the prostate (TURP) is considered gold standard for surgical treatment of benign prostatic hyperplasia (BPH). In this study, we aimed to compare post-operative clinical outcomes and adverse effects between monopolar and bipolar TURPs. MATERIALS AND METHODS: The study included 590 patients who underwent TURP by a single urologist (E.H.) between June 2006 and June 2014 with a diagnosis of BPH. Patients were divided into two groups as monopolar TURP (group 1, n = 300) and bipolar TURP (group 2, n = 290). Patients receiving oral anticoagulants or aspirin and those with prostate cancer diagnosis were not included in the study. Data regarding pre-operative age, International Prostate Symptom Score (IPSS), maximum urinary flow rate (Qmax), post voiding residual urine volume (PVR), serum prostate specific antigen (PSA) levels and prostate volume (Vp) of the patients were gathered from medical records. Groups were compared in terms of catheterization, operation time, hemoglobin (Hb) decrease, and IPSS, Qmax, and PVR values at post-operative 12th month follow-up visit. RESULTS: From pre-operative to post-operative period, IPSS, Qmax and PVR showed significant improvements within both groups (P < .001). When groups were compared with each other, bipolar TURP group had significantly lesser catheterization time and hemoglobin decrease than monopolar TURP group, while no significant differences were detected regarding all other variables. CONCLUSION: Bipolar and monopolar TURPs are both effective and safe treatment modality for BPH. Bipolar TURP is superior to conventional monopolar TURP in terms of catheterization time and Hb decrease.


Asunto(s)
Hiperplasia Prostática/cirugía , Prostatismo/cirugía , Resección Transuretral de la Próstata/métodos , Anciano , Hemoglobinas/metabolismo , Humanos , Masculino , Persona de Mediana Edad , Tempo Operativo , Hiperplasia Prostática/complicaciones , Hiperplasia Prostática/fisiopatología , Prostatismo/etiología , Prostatismo/fisiopatología , Índice de Severidad de la Enfermedad , Factores de Tiempo , Resección Transuretral de la Próstata/efectos adversos , Resultado del Tratamiento , Cateterismo Urinario , Urodinámica
3.
Urology ; 78(4): 968.e1-6, 2011 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-21872909

RESUMEN

OBJECTIVE: To evaluate the mechanism of action of imatinib mesylate (Gleevec), a protein tyrosine kinase inhibitor on the human prostate with benign prostatic hyperplasia. METHODS: Prostate samples were obtained from 16 patients with benign prostatic hyperplasia (mean age 68.3 ± 1.9 years), who had undergone transurethral prostatectomy. In tissue bath studies, cumulative concentration-response curves were constructed for imatinib after precontraction with 120 mM KCl. Imatinib-induced relaxation was quantitated in tissues treated with l-N(G)-Nitroarginine Methyl Ester (l-NAME) (an inhibitor of nitric oxide synthase) or 1H-[1,2,4]-oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) (a soluble guanylyl cyclase inhibitor). Two K+ channel blockers (adenosine triphosphate [K(ATP)] and Large-conductance Ca(2+)-activated K(+) channels [BK(Ca2+)] channels) were also evaluated as antagonists of imatinib-induced relaxation and repeated in the presence of the α-adrenergic receptor blocker alfuzosin. An electrical field stimulation (1-20 Hz, 5 ms, 5 seconds, 60 V)-induced contractile response was performed on strips incubated with imatinib (10(-3) M). RESULTS: KCl-induced contractions in human prostatic tissue were significantly inhibited by imatinib (maximal response 84.9 ± 4.5%) and were attenuated by l-NAME (42%, P < .001) and ODQ (43%, P < .001). This relaxant effect was also suppressed by glibenclamide (adenosine triphosphate-sensitive K+ channel blocker, 41%, P < .001) and tetraethylammonium (BK(Ca2+) channel blocker, 24%, P < .05). CONCLUSION: Imatinib induced prostatic smooth muscle relaxation in vitro. This effect was suppressed by l-NAME and ODQ, showing a dependence on the nitric oxide-cyclic guanosine monophosphate pathway and modulated by the K(ATP) and BK(Ca2+) K+ channels. Our findings suggest that imatinib can augment relaxation of human prostatic tissues by way of a novel ligand-protein tyrosine kinase signaling pathway.


Asunto(s)
Relajación Muscular/efectos de los fármacos , Músculo Liso/efectos de los fármacos , Piperazinas/uso terapéutico , Próstata/efectos de los fármacos , Próstata/enzimología , Proteínas Tirosina Quinasas/antagonistas & inhibidores , Pirimidinas/uso terapéutico , Antagonistas Adrenérgicos alfa/farmacología , Anciano , Benzamidas , Humanos , Hiperplasia/patología , Mesilato de Imatinib , Masculino , Persona de Mediana Edad , Contracción Muscular , NG-Nitroarginina Metil Éster/farmacología , Piperazinas/farmacología , Enfermedades de la Próstata/patología , Inhibidores de Proteínas Quinasas/uso terapéutico , Pirimidinas/farmacología , Quinazolinas/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA